News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CyDex, Inc. Licenses Captisol(R) to Critical Therapeutics for Injectable Formulation of Zileuton



6/12/2007 2:12:35 PM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced the signing of a license and supply agreement granting exclusive worldwide rights to its Captisol® enabling technology to Critical Therapeutics, Inc. (NASDAQ: CRTX) for the development of an injectable formulation of zileuton.

Read at press release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES